Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | PNPLA2 | Q96AD5 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902072 | 0.92 | RXRA (0.46) | RXRANR1H2NR1H3TP53KDM4E | |
| SCHEMBL14184090 | 0.90 | RXRA (0.44) | RXRANR1H2NR1H3TP53KDM4E | |
| SCHEMBL4904313 | 0.88 | RXRA (0.42) | RXRANR1H2NR1H3MCHR1KDM4E | |
| SCHEMBL4901943 | 0.88 | RXRA (0.40) | RXRANR1H2NR1H3MCHR1 | |
| SCHEMBL14184095 | 0.87 | RXRA (0.40) | RXRANR1H2NR1H3MCHR1KDM4E | |
| SCHEMBL4902420 | 0.87 | RXRA (0.39) | RXRANR1H2NR1H3MCHR1 | |
| SCHEMBL4906577 | 0.86 | RXRA (0.44) | RXRANR1H2NR1H3MCHR1KDM4E | |
| SCHEMBL14184092 | 0.86 | MET (0.40) | RXRANR1H2NR1H3MCHR1 | |
| SCHEMBL4905525 | 0.85 | NR1H2 (0.46) | RXRANR1H2NR1H3KDM4EMAPT | |
| SCHEMBL4901856 | 0.84 | NR1H2 (0.47) | RXRANR1H2NR1H3KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | claimed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | RXRA 20/4885NR1H2 1/4885NR1H3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.